Allurion Catapults Nearly 200% On Its Plans To Outdo Eli Lilly, Novo Nordisk
Allurion Catapults Nearly 200% On Its Plans To Outdo Eli Lilly, Novo Nordisk

Allurion catapulted nearly 200% early Friday after the company said it plans to test its weight-loss technology with an obesity drug. 

​ Read MoreYahoo Canada Sports – Sports News, Scores, Rumours, Fantasy Games, and more